Skip to main content
ALGORAE PHARMACEUTICALS LIMITED logo

ALGORAE PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · 1AI ISIN · AU0000296022 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,159 across all filing types
Latest filing 2013-10-27 Investor Presentation
Country AU Australia
Listing ASX 1AI

About ALGORAE PHARMACEUTICALS LIMITED

https://algoraepharma.com/

Algorae Pharmaceuticals Limited is a biopharmaceutical company focused on the discovery and development of novel therapeutic solutions for complex medical conditions. The company leverages its proprietary artificial intelligence platform, AlgoraeOS, to streamline the drug discovery process and identify synergistic drug combinations. Its research pipeline primarily targets neurodegenerative diseases and other areas of high unmet clinical need. Key development programs include AI-116, a combination therapy aimed at treating dementia and Alzheimer's disease. By integrating advanced computational modeling with traditional pharmacological research, the company seeks to accelerate the transition of candidates from preclinical stages to clinical trials, optimizing therapeutic efficacy and safety profiles.

Recent filings

Filing Released Lang Actions
Australia Biotech Invest 2013 20 pages 1.5MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about LCT Global's cell therapy products, clinical development progress, partnerships, and scientific background. It includes forward-looking statements and promotional content aimed at investors. There are no financial statements, regulatory filings, voting results, or management changes. The content is consistent with an investor presentation focusing on company strategy, product pipeline, and market potential rather than a formal report or announcement. The length and detail also support this classification rather than a brief announcement or regulatory filing.
2013-10-27 English
Notice of Annual General Meeting/Proxy Form 12 pages 99.6KB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' for Living Cell Technologies Limited, detailing the date, location, and agenda of the AGM. It includes resolutions to be voted on, such as adoption of the remuneration report, re-election of directors, and approval of share option plans. The text references the Annual Report for the year ended 30 June 2013 but does not contain the report itself. It is a notice informing shareholders about the meeting and the business to be conducted, consistent with an AGM Information document. The document length is about 15,000 characters, which is typical for a detailed AGM notice including explanatory notes and voting instructions. There is no actual financial data or full report content, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a voting results announcement (DVA) as it precedes the meeting. Therefore, the correct classification is AGM Information (AGM-R).
2013-10-14 English
Annual Report to shareholders 56 pages 3.9MB
Regulatory Filings
2013-10-14 English
First patient successfully implanted with NTCELL 4 pages 148.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Living Cell Technologies Limited dated 20th September 2013. It reports the successful first patient implant in a Phase I clinical trial of a regenerative cell therapy for Parkinson's disease. The content focuses on clinical trial progress, scientific background, and partnership funding details. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a corporate announcement about a clinical milestone and funding arrangements, not a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just a notice of report availability. The document fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about clinical trial progress and funding, which does not fit other specific categories like Annual Report, Earnings Release, or Capital Update.
2013-09-19 English
Publication of pre-clinical trial of NTCELL in Parkinson's 3 pages 29.7KB
Regulatory Filings Classification · 90% confidence The document is an ASX announcement from Living Cell Technologies Limited about the publication of a successful pre-clinical trial of their product NTCELL for Parkinson's disease. It discusses the scientific results, ongoing Phase I clinical trials, and funding arrangements. The document is an announcement of the publication of a scientific study and clinical trial progress, not a financial report, regulatory filing, or management report. It does not contain financial statements, voting results, or executive changes. The content is primarily a news release about scientific and clinical progress, which fits best under a general regulatory announcement category. Given the nature and length of the document (8427 characters), it is not a brief factsheet or a report publication announcement. It is best classified as a Regulatory Filing (RNS) as a general announcement that does not fit other specific categories.
2013-09-15 English
Appendix 4E and Financial Statements 61 pages 669.2KB
Regulatory Filings
2013-08-29 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.